Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24723912 | 0.86 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL25017777 | 0.85 | CYP2C9 (0.42) | CYP2C9CYP2C19ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL24723914 | 0.84 | NPC1 (0.41) | DGAT1ALDH1A1SMN1; SMN2NPC1S1PR4 | |
| SCHEMBL30908132 | 0.82 | DGAT1 (0.39) | CYP2C9CYP2C19DGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2965634 | 0.81 | NPC1 (0.39) | DGAT1ALDH1A1CA1CA2NPC1 | |
| SCHEMBL26915876 | 0.81 | NPC1 (0.36) | DGAT1NPC1L3MBTL1 | |
| SCHEMBL28753181 | 0.80 | RAB9A (0.41) | DGAT1ALDH1A1CA12CA1CA2 | |
| SCHEMBL29627173 | 0.80 | RAB9A (0.41) | DGAT1ALDH1A1CA12CA1CA2 | |
| SCHEMBL2960376 | 0.80 | CA12 (0.40) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL15726275 | 0.80 | DGAT1 (0.38) | CYP2C9CYP2C19DGAT1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | claimed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4076448-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114980887-A | Fluoroalkyl-oxadiazoles and their use | 特纳亚治疗股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| EP-2079730-A1 | MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008041075-A1 | MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | CYP2C9 830/4885CYP2C19 607/4885DGAT1 4146/4885 |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CYP2C9 3897/4885CYP2C19 2927/4885DGAT1 825/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | CYP2C9 3920/4885CYP2C19 3904/4885DGAT1 1498/4885 |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CYP2C9 4517/4885CYP2C19 4139/4885DGAT1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.